biotech · Melanoma · Psoriasis · PVCT
Provectus Biopharmaceuticals
PROVECTUS BIOPHARMACEUTICALS, INC.
Provectus Biopharmaceuticals clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Knoxville, Tennessee 37932, US
- Founded
- 2004
- Employees
- 7
- Programs
- 12
- Drugs
- 5
- Patents
- 29
Provectus Biopharmaceuticals projects
4 ClinicalTrials.gov programs sponsored by Provectus Biopharmaceuticals.
Provectus Biopharmaceuticals has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
PV-10 (10% rose bengal disodium)
PROVECTUS BIOPHARMACEUTICALS, INC.
Cancer Metastatic to the Liver
1 trial -
PV-10 (rose bengal disodium 10%)
PROVECTUS BIOPHARMACEUTICALS, INC.
Breast Cancer
1 trial -
PV-10 (rose bengal disodium, 10%)
PROVECTUS BIOPHARMACEUTICALS, INC.
Melanoma
1 trial -
Rose bengal disodium
PROVECTUS BIOPHARMACEUTICALS, INC.
Neuroendocrine Tumors Metastatic to the Liver
1 trial
Frequently asked questions
How many clinical projects does Provectus Biopharmaceuticals have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.